2019-05-13T16:44:08-05:00 2018-09-30 953309779 GURSEY SCHNEIDER LLP 1888 CENTURY PARK EAST SUITE 900 LOS ANGELES CA 900671735 990 2017-10-01 954296919 INTERNATIONAL MYELOMA FOUNDATION INTE 8184877455 12650 RIVERSIDE DRIVE NO 206 NORTH HOLLYWOOD CA 916073466 SUSAN DURIE PRESIDENT 8184877455 2019-05-13 1 NAZ AFSHAR P00441843 3105520960 38.104.231.98 2019-05-13 16:32:56 PD P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 EA673CAE559EF0374FCFAF59F4B8E3C23DD0614C 2017 2019-02-21 02:37:17Z SUSAN DURIE 12650 RIVERSIDE DRIVE SUITE 206 NORTH HOLLYWOOD CA 91607 17206768 0 X WWW.MYELOMA.ORG X 1990 CA DEDICATED TO IMPROVING THE QUALITY OF LIFE OF MYELOMA PATIENTS WHILE WORKING TOWARD PREVENTION AND A CURE. 18 17 46 34 0 11000 15589432 16653578 59198 59459 347381 329426 -306854 -238441 15689157 16804022 525686 423333 0 0 4561892 5367547 0 0 926190 10937843 11093027 16025421 16883907 -336264 -79885 19253565 16649778 11171352 8647450 8082213 8002328 X DEDICATED TO IMPROVING THE QUALITY OF LIFE OF MYELOMA PATIENTS WHILE WORKING TOWARD PREVENTION AND A CURE. 0 0 6762950 423333 RESEARCH - THE FOUNDATION IS THE LEADER IN GLOBALLY COLLABORATIVE MYELOMA RESEARCH. FOUNDATION SUPPORTS LAB-BASED RESEARCH AND HAS AWARDED OVER 142 GRANTS TO TOP JUNIOR AND SENIOR RESEARCH SCIENTISTS SINCE 1995. IN ADDITION, THE FOUNDATION BRINGS TOGETHER THE WORLD'S LEADING EXPERTS IN THE MOST SUCCESSFUL AND UNIQUE WAY THROUGH THE INTERNATIONAL MYELOMA WORKING GROUP, WHICH IS PUBLISHING IN PRESTIGIOUS MEDICAL JOURNALS, CHARTING THE COURSE TO A CURE, MENTORING THE NEXT GENERATION OF INNOVATIVE INVESTIGATORS, AND IMPROVING LIVES THROUGH BETTER CARE. THE BLACK SWAN RESEARCH INITIATIVE IS A MULTINATIONAL CONSORTIUM OF LEADING MYELOMA EXPERTS WHO ARE HARNESSING NEW TECHNOLOGIES AND THE LATEST MYELOMA TREATMENTS TO FIND A PATHWAY TO A CURE. THE BLACK SWAN RESEARCH STRATEGY CAPITALIZES ON THE AVAILABILITY OF POTENT NOVEL THERAPIES AND THE ADVENT OF ULTRA-SENSITIVE TESTS TO MEASURE EXACTLY WHEN AND HOW THOSE THERAPIES ARE WORKING IN PATIENTS. THE BLACK SWAN RESEARCH INITIATIVE IS DEDICATED TO DEVELOPING NEW CURATIVE THERAPIES FOR MYELOMA. 1104873 27733 PATIENT AND FAMILY SEMINARS: THE IMF'S PATIENT AND FAMILY SEMINARS PRESENT VITAL INFORMATION ABOUT NEW TREATMENTS AND CLINICAL TRIALS, PROVIDE TIME WITH MYELOMA SPECIALISTS IN INTIMATE SETTINGS, AND ALLOW PARTICIPANTS TO SHARE THEIR PERSONAL EXPERIENCES AND SUPPORT. PREMIER MYELOMA EXPERTS VOLUNTEER THEIR TIME TO THE SEMINARS, TO EMPOWER PATIENTS AND THEIR FAMILIES TO MAKE EDUCATED TREATMENT CHOICES TAILORED TO THEIR NEEDS. IN ADDITION TO PATIENT AND FAMILY SEMINARS, THE IMF FACILITATES REGIONAL COMMUNITY WORKSHOPS, WHICH SERVE AS CONDENSED SEMINARS IN SMALLER CITIES TO EXPAND THE REACH OF IMF PROGRAMS AND UP-TO-DATE INFORMATION ON MYELOMA CARE, SUPPORT AND TREATMENT TO A WIDER AUDIENCE AT NO CHARGE. 1815666 EDUCATION AND AWARENESS: ALTHOUGH IT IS THE SECOND MOST COMMON BLOOD CANCER, MULTIPLE MYELOMA IS STILL A RELATIVELY UNKNOWN DISEASE. FOR MANY PATIENTS AND THEIR CAREGIVERS, IT IS AT DIAGNOSIS WHEN THEY FIRST HEARD THE WORD "MYELOMA". THE INTERNATIONAL MYELOMA FOUNDATION (IMF) RECOGNIZES THE NEED FOR COMPREHENSIVE EDUCATION PROGRAMS FOR BOTH THE PATIENT AND THE PHYSICIAN TO ENSURE THAT PATIENTS ARE DIAGNOSED CORRECTLY AND TREATED EFFECTIVELY. OUR LIBRARY OF MORE THAN 100 PUBLICATIONS FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS, IS AVAILABLE FREE OF CHARGE. PUBLICATIONS ARE UPDATED ANNUALLY AND AVAILABLE IN MORE THAN 20 LANGUAGES. THE IMF EMPOWERS PATIENTS AND THEIR CAREGIVERS TO JOIN HEALTHCARE PROVIDERS AS ACTIVE DECISION-MAKING PARTNERS, LEADING TO THE BEST POSSIBLE QUALITY OF LIFE FOR EACH INDIVIDUAL MYELOMA PATIENT. THE IMF PRODUCES COMPREHENSIVE BUT 'USER-FRIENDLY' INFORMATION FOR THE ENTIRE MYELOMA COMMUNITY. THE IMF'S PUBLICATIONS LIBRARY INCLUDES AN EXTENSIVE CATALOG OF BOOKLETS, TIP CARDS, ARTICLES, AND TELECONFERENCES, BLOGS, DIGITAL MEDIA AND INTERVIEWS, ALL WRITTEN, CREATED, AND PRODUCED BY THE IMF WITH OVERSIGHT BY ITS SCIENTIFIC ADVISORY COMMITTEE. THE IMF LIBRARY'S BROAD SCOPE INCLUDES INFORMATION ABOUT MYELOMA TREATMENT OPTIONS, CLINICAL TRIALS, AND QUALITY OF LIFE CONSIDERATIONS FOR PATIENTS AND PHYSICIANS. 1313091 INTERNATIONAL - THE IMF GROWS ITS NETWORK OF HEALTH CARE PROFESSIONALS AROUND THE WORLD. KEY TEAM MEMBERS ORGANIZE PHYSICIAN AS WELL AS PATIENT MEETINGS IN ORDER TO PROVIDE EDUCATION ABOUT THE LATEST DEVELOPMENTS IN THE FIELD OF MULTIPLE MYELOMA. 975130 31726 SUPPORT GROUPS: THROUGH A GLOBAL COMMUNITY OF ASSISTED SUPPORT GROUPS, THE IMF SEEKS TO ENSURE THAT PATIENTS AND FAMILIES HAVE LOCAL ACCESS TO SUPPORT AND EDUCATION. THE IMF CURRENTLY SUPPORTS OVER 300 SUPPORT GROUPS WORLDWIDE. THE IMF OFFERS UNEQUALED WEBSITE CREATION AND HOSTING FOR LOCAL SUPPORT GROUPS, AND PROVIDED A UNIQUE OPPORTUNITY FOR SOME SUPPORT GROUP LEADERS TO ATTEND THE AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING. THE 18TH ANNUAL SUPPORT GROUP LEADERS SUMMIT TOOK PLACE WITH OVER 100 LEADERS IN ATTENDANCE. THE SUPPORT GROUPS REPRESENTED AT THE SUMMIT SERVE MORE THAN 5,300 SUPPORT GROUP MEMBERS, EXTENDING THE SUMMIT'S REACH TO THOUSANDS OF MYELOMA PATIENTS AND FAMILY MEMBERS. TECHNOLOGY IS ALSO EMPHASIZED FOR SUPPORT GROUP LEADERS. THE IMF ALSO CONTINUED TO UPDATE ITS APP SPECIFICALLY DESIGNED FOR SUPPORT GROUP LEADERS WHICH OFFER A SAMPLE MEETING AGENDAS AND GROUP SURVEYS, AS WELL AS VIDEOS, BLOGS, WEBCASTS, AND SLIDE PRESENTATIONS THAT CAN BE UTILIZED DURING MEETINGS. 673083 NURSE - THE IMF NURSE LEADERSHIP BOARD IS A PROFESSIONAL PARTNERSHIP REPRESENTING NURSE EXPERTS CARING FOR MYELOMA PATIENTS AT LEADING MEDICAL CENTERS. FOUNDED IN NOVEMBER 2006, THE NLB HAS PROVEN TO BE INVALUABLE TO THE MYELOMA COMMUNITY AS A PLATFORM THAT BOLSTERS NURSING EDUCATION, CLINICAL CARE EXPERIENCE EXCHANGE, AND PATIENT KNOWLEDGE AND EMPOWERMENT IN AN EFFORT TO OPTIMIZE OUTCOMES FOR PATIENTS WITH MYELOMA. THIS BOARD OF EXPERIENCED MYELOMA NURSES HAS MADE GREAT STRIDES IN IMPROVING THE NURSING CARE AND SELF-CARE OF MYELOMA PATIENTS SINCE ITS INCEPTION. 769253 CLINICAL MEETINGS - IMF TEAM MEMBERS ORGANIZE CLINICAL MEETINGS, BRINGING TOGETHER THE WORLD'S LEADING MYELOMA EXPERTS, TO FORM A COALITION THAT WILL WORK COLLABORATIVELY ON MYELOMA-RELATED PROJECTS AND AVOID DUPLICATION OF EFFORTS AND DILUTION OF VALUABLE RESOURCES. THESE COALITIONS PROMOTE EXCELLENCE IN CLINICAL PRACTICE, RESEARCH AND EDUCATION AND CME-ACCREDITED MEDICAL EDUCATION PROGRAMS. THIS PAST YEAR ALSO INCLUDED EDUCATION TO THE COMMUNITY PHYSICIAN AND NURSE VIA ONLINE AND LIVE INSTRUCTION. 654934 ADVOCACY - THE IMF IS DEDICATED TO CREATING A GLOBAL COMMUNITY THAT SUPPORTS THE WIDE-RANGING NEEDS OF ALL AFFECTED BY MYELOMA. THE IMF ADVOCATES ON BEHALF OF THOSE AFFECTED BY MULTIPLE MYELOMA FOR AN INCREASE IN ACCESSIBILITY OF HIGH-QUALITY DIAGNOSTICS AND TREATMENTS, FOR FUNDING OF MYELOMA-RELATED RESEARCH, AND FOR AN END TO INSURANCE COVERAGE DISPARITIES FOR TREATMENT. THE IMF INCLUDES THE ENTIRE MYELOMA COMMUNITY IN THESE EFFORTS AND CONTINUES TO EXPAND ITS COMMITMENT TO EMPOWERING PATIENTS, FAMILIES, AND FRIENDS TO ADVOCATE ON BEHALF OF PATIENT RIGHTS. 370714 INFOLINE - THE IMF'S TOLL-FREE INFORMATION TELEPHONE LINE PROVIDES LIFE-SAVING AND LIFE-CHANGING MYELOMA TREATMENT AND MANAGEMENT SUPPORT FROM COMPASSIONATE, HIGHLY TRAINED SPECIALISTS. AS NEW TREATMENT OPTIONS ARE GAINING ATTENTION AND USE IN MULTIPLE MYELOMA, ANSWERING QUESTIONS ABOUT MYELOMA, ITS TREATMENT, DRUG SIDE EFFECTS, OPTIONS FOR POSSIBLE CLINICAL TRIALS OTHER HEALTH CONCERNS, AND WHERE TO FIND LOCAL SUPPORT IS MORE IMPORTANT THAN EVER. 363616 WEBSITE - THE IMF WEBSITE IS A LEADING RESOURCE FOR MYELOMA-RELATED CONTENT AND THE MOST COMPLETE SOURCE OF ANSWERS TO THE MANY QUESTIONS ASKED BY THOSE NEWLY DIAGNOSED. THE IMF OFFERS PATIENTS AND CAREGIVERS MULTI-LINGUAL ACCESS TO ALL CURRENT MYELOMA RESEARCH (IMF-FUNDED RESEARCH AND OTHERWISE), THE LATEST COMMUNITY DEVELOPMENTS, AND LINKAGE TO SUPPORT SERVICES AND ADVOCACY FORUMS. IT ALSO PROVIDES ACCESS TO DR.BRIAN G.M. DURIE'S 10 STEPS TO BETTER CARE(R), A UNIQUE TOOL FOR DIAGNOSTIC AND TREATMENT INFORMATION WHICH IS DESIGNED TO HELP BOTH PATIENTS AND PHYSICIANS BETTER NAVIGATE THE COURSE OF MYELOMA, FROM DIAGNOSIS THROUGH LONG-TERM SURVIVAL. 296892 MYELOMA TODAY - MYELOMA TODAY IS A QUARTERLY NEWSLETTER AND THE GO-TO RESOURCE FOR THE MYELOMA COMMUNITY TO LEARN ABOUT THE LATEST ADVANCES IN MYELOMA TREATMENT, RESEARCH AND QUALITY OF LIFE ISSUES. IT IS PROVIDED FREE OF CHARGE. 125781 INFORMATIONAL MAILINGS - THE INFOPACK IS MADE UP OF A SELECTION OF THE IMF'S PUBLICATIONS AND IS DESIGNED TO PROVIDE NEWLY DIAGNOSED PATIENTS AND THEIR FAMILIES WITH A COMPLETE UNDERSTANDING OF THE DISEASE AND CARE. THE INFO PACK CONTAINS INFORMATIVE MATERIALS FREE OF CHARGE IN 20 LANGUAGES. 5542494 31726 15225983 1 1 0 1 0 0 0 0 0 0 1 1 0 0 1 1 1 0 0 1 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 33 0 1 46 1 1 1 0 0 0 0 1 1 0 0 0 0 X 18 17 1 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT DC FL GA HI IL KS KY ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X X JENNIFER SCARNE 8184877455 12650 RIVERSIDE DRIVE 206 NORTH HOLLYWOOD CA 91607 DR BRIAN DURIE CHAIRMAN 1.00 X 0 0 0 SUSAN DURIE PRESIDENT 40.00 X X 245000 0 35152 BENSON KLEIN DIRECTOR 1.00 X 0 0 0 DR ROBERT A KYLE DIRECTOR 1.00 X 0 0 0 DR EDITH MITCHELL DIRECTOR 1.00 X 0 0 0 CHARLES NEWMAN DIRECTOR 1.00 X 0 0 0 MATTHEW ROBINSON DIRECTOR 1.00 X 0 0 0 E MICHAEL D SCOTT DIRECTOR 1.00 X 0 0 0 LORAINE BOYLE DIRECTOR 1.00 X 0 0 0 DR VINCENT RAJKUMAR DIRECTOR 1.00 X 0 0 0 DR MARIO BOCCADORO DIRECTOR 1.00 X 0 0 0 ANDREW KUZNESKI III DIRECTOR 1.00 X 0 0 0 DR HEINZ LUDWIG DIRECTOR 1.00 X 0 0 0 CHRISTINE BATTISTINI DIRECTOR 1.00 X 0 0 0 ALDO DEL COL DIRECTOR 1.00 X 0 0 0 YELAK BIRU DIRECTOR 1.00 X 0 0 0 JASON KATZ DIRECTOR 1.00 X 0 0 0 GEORGE T HAYUM DIRECTOR 1.00 X 0 0 0 JENNIFER SCARNE CFO/COO 40.00 X 265000 0 20541 LISA PAIK SENIOR VICE PRESIDENT 40.00 X 173875 0 23554 DIANE MORAN STRATEGIC PLANNER 40.00 X 251250 0 17576 935125 0 96823 14 1 1 1 DAN NAVID SIRA SILA 20/46 SOI 97 HUA HIN TH 77110 INTERNATIONAL GLOBAL STRATEGY 198000 DRINKER BIDDLE & REATH LLP ONE LOGAN SQUARE STE 2000 PHILIDELPHIA PA 19103 ADVOCACY CONSULTING SERVICES 150000 2 971893 15681685 16653578 SUPPORT GROUP 611710 31726 31726 PATIENT & FAMILY SEMINARS 611710 27733 27733 59459 181614 181614 147812 0 147812 147812 147812 164305 971893 402746 -238441 -238441 16804022 59459 0 90985 X 130000 130000 293333 293333 5367547 4398112 417029 552406 172592 126337 44707 1548 52166 44424 5373 2369 1728954 1706867 15000 7087 279105 243661 7149 28295 163341 140075 10671 12595 299870 221931 34910 43029 1203792 1169747 5744 28301 2710794 2564087 77005 69702 212210 189390 11464 11356 121934 89921 28989 3024 PRINTING & PUBLICATIONS 3689958 3670007 19951 POSTAGE & SHIPPING 178835 69242 3383 106210 TELEPHONE 120068 105235 3813 11020 RECRUITMENT 61828 61828 97580 63614 4669 29297 16883907 15225983 731734 926190 1324797 548806 790201 1566173 10184182 7041588 894936 1287362 1478702 550357 878776 928345 5079916 5146943 100757 130561 19253565 16649778 1731656 1506735 9434342 7062437 5354 78278 11171352 8647450 X 7929306 6338900 152907 1663428 8082213 8002328 19253565 16649778 -79885 0 X X 0 1 X 1 0 X 13731918 12769438 11394264 9690465 11470224 59056309 13731918 12769438 11394264 9690465 11470224 59056309 30777641 28278668 27046 128518 197754 170097 134827 658242 59714551 382892 0.47360 0.42030 X SCHEDULE A, PART VI, LIST OF UNUSUAL GRANTS: DESCRIPTION: BLACK SWAN RESEARCH INITIATIVE - SPECIALIZED RESEARCH PROJECT DATE: 09/30/18 AMOUNT: 4455000. DESCRIPTION: SPECIALIZED RESEARCH DATE: 09/30/18 AMOUNT: 365750. DESCRIPTION: CLINICAL TRIAL ACCRUALS DATE: 09/30/18 AMOUNT: 159460. DESCRIPTION: NURSE LEADERSHIP BOARD MEETING DATE: 09/30/18 AMOUNT: 200000. 43144 191475 234619 15704337 15938956 946948 236737 0 0 749357 902384 902008 946948 3500697 5251046 288736 231437 202131 234619 956923 187339 225596 225502 236737 875174 1312761 137253 78841 39381 43144 298619 1478702 550357 928345 928345 SMITH BARNEY 128045 C EQUITIES - FRB 1998 LT 1847482 F MUTUAL FUND - FRB 1998 LT 318342 F MUTUAL FUND - MS SMITH BARNEY INV. 12-562 2332349 F EQUITIES - MS SMITH BARNEY INV. 12-562 520725 F 5146943 ANNUITY PYMT LIABILITY 78278 78278 X 16785261 0 16785261 18761 18761 16804022 16865146 0 16865146 18761 18761 16883907 PART X, LINE 2: MANAGEMENT HAS ANALYZED THE TAX POSITIONS TAKEN BY THE ENTITY AND HAS CONCLUDED THAT AS OF SEPTEMBER 30, 2018, THERE WERE NO UNCERTAIN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN. ACCORDINGLY, NO INTEREST OR PENALTIES RELATED TO UNCERTAIN TAX POSITIONS WERE ACCRUED IN THE ACCOMPANYING FINANCIAL STATEMENTS. THE ENTITY IS SUBJECT TO AUDITS BY TAXING JURISDICTIONS, HOWEVER, NO AUDITS FOR ANY TAX PERIODS ARE CURRENTLY IN PROGRESS. MANAGEMENT BELIEVES THAT THE ENTITY IS NO LONGER SUBJECT TO INCOME TAX EXAMINATIONS FOR YEARS ENDED ON OR PRIOR TO SEPTEMBER 30, 2013 UNDER FEDERAL AND CALIFORNIA TAX JURISDICTIONS. PART XI, LINE 4B - OTHER ADJUSTMENTS: REFUND RECEIVED OF PRIOR YEAR RESEARCH GRANT PART XII, LINE 4B - OTHER ADJUSTMENTS: REFUND RECEIVED OF PRIOR YEAR RESEARCH GRANT 0 EUROPE 1 1 PROGRAM SERVICES AWARDED RESEARCH GRANTS, CONDUCTED A RESEARCH PROJECT, PATIENT & FAMILY SEMINARS, PATIENT AND PHYSICIAN REGIONAL COMMUNITY WORKSHOPS, AND AN AWARDS CEREMONY. 4026272 EAST ASIA AND THE PACIFIC 1 1 PROGRAM SERVICES AWARDED RESEARCH GRANTS, CONDUCTED A RESEARCH PROJECT, PATIENT & FAMILY SEMINARS, PATIENT AND PHYSICIAN REGIONAL COMMUNITY WORKSHOPS. 911462 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 PROGRAM SERVICES 106114 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES 7867 2 2 0 0 2 2 5051715 0 5051715 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM DECIPHERING THE ROLE OF ERNAS IN THE PATHOGENESIS OF MM 26667 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM TARGETING RESIDUAL, DORMANT CANCER CELLS IN THE M: A NEW APPROACH 26667 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM METABOLISM WITHIN THE BONE MARROW MICROENVIRONMENT: TARGETS FOR MM STRATEGY 53333 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) IN MM: PIVOTAL ROLE IN GENOMIC INSTABILITY AND DRUG RESPONSE? 33333 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM TARGETING OF BMI-1 AS NOVEL TREATMENT OPTION IN MM: EXAMINATION OF PTC-028 AS PUTATIVE ANTI-MYELOMA DRUG IN VITRO & IN VIVO 16667 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM EXPLOITING ID01-GCN2-P62 AXIS IN MM MICOENVIRONMENT TO TRIGGER MYELOID DERIVE SUPPRESSORS CELLS IN MM 16667 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM THE RIBONUCLEASE DIS3 IN THE DNA DAMAGE RESPONSE IN MYELOMA: A TARGETABLE PATHWAY TO PROTECT THE GENOME. 33333 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM REPROGRAMMING MM CELL METABOLISHM TO AFFECT BONE DISEASE IN MULTIPLE MYELOMA 53333 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, TISSUE ENGINEERING OF AN ORTHOTOPIC HUMANISED BONE-ORGAN AS A PRECLINICAL PLATFORM FOR MULTIPLE MYELOMA RESEARCH 33333 0 0 0 0 0 0 PART I, LINE 2: FOR RESEARCH GRANT FUNDS, REPORTS ARE PROVIDED AS PART OF THE REQUIRED GRANT COMPLIANCE PROCESS BUILT INTO THE GRANT AGREEMENT. GALA 1136198 971893 164305 402746 1136198 971893 164305 402746 402746 -238441 N/A 0 DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVE BOSTON MA 02115 042263040 IRS SEC 501(C)(3) 70000 TREATING MYELOMA THROUGH INDUCING DEGRADATION OF BET BROMODOMAIN PROTEINS, BLOOD BIOMARKERS FOR CLONAL PROGRESSION IN MULTIPLE MYELOMA AND INVESTIGATING THE ROLE OF ROBO1 IN MIGRATION AND HOMING IN MULTIPLE MYELOMA. HUNTSMAN CANCER INSTITUTE UNIVERSITY OF UTAH 2000 CIRCLE OF HOPE SALT LAKE CITY UT 84112 876000526 IRS SEC 501(C)(3) 43333 GENERATION AND VALIDATION OF A MONOCLONAL ANTIBODY AGAINST VISTA FOR THE IMMUNOMODULATORY THERAPY OF MM AND ANTI-CD229 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR TREATMENT OF MM. INDIANA UNIVERSITY SCHOOL OF MEDICINE 340 WEST 10TH STREET INDIANAPOLIS IN 46202 356001673 IRS SEC 501(C)(3) 16667 BONE/BONE MARROW=TARGETED INHIBITION OF NOTCH SIGNALING IN COMBINATION WITH GLUCOCORTICOID THERAPY AS A NOVEL APPROACH TO TREAT MM. 1 X 0 0 0 0 0 0 0 1 0 SUSAN DURIE PRESIDENT 215000 0 30000 0 0 0 0 0 0 0 245000 0 0 0 JENNIFER SCARNE CFO/COO 250000 0 15000 0 0 0 0 0 0 0 265000 0 0 0 LISA PAIK SENIOR VICE PRESIDENT 173875 0 0 0 0 0 0 0 0 0 173875 0 0 0 DIANE MORAN STRATEGIC PLANNER 231250 0 20000 0 0 0 0 0 0 0 251250 0 0 0 PART I, LINE 7 BONUSES PAID: SUSAN LAVITT NOVIS - $30,000 DIANE MORAN - $20,000 JENNIFER SCARNE - $15,000 FORM 990, PART VII LINE 5 CHAIRMAN, DR. BRIAN DURIE, WAS COMPENSATED $195,000 FROM THE DURIE GROUP FOR SERVICES RENDERED TO THE ORGANIZATION. FORM 990, PART VI, SECTION A, LINE 2 SUSAN NOVIS, PRESIDENT AND DR. BRIAN DURIE, CHAIRMAN ARE HUSBAND AND WIFE. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE FORM 990 IS PROVIDED TO THE FINANCE COMMITTEE OF THE BOARD FOR REVIEW PRIOR TO FILING THE TAX RETURN. FORM 990, PART VI, SECTION B, LINE 12C THIS PROCEDURE IS PERFORMED ANNUALLY AT THE ORGANIZATION'S BOARD OF DIRECTORS RETREAT. FORM 990, PART VI, SECTION B, LINE 15 FOR KEY EMPLOYEES, A REVIEW OF COMPARABLE COMPENSATION DATA IS REVIEWED BY THE FINANCE COMMITTEE. MEMBERS OF THE FINANCE COMMITTEE APPROVE OF THE COMPENSATION PACKAGE AND WOULD NOT HAVE A CONFLICT OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT ISSUE. THE DECISION IS DISCUSSED AND RECORDED IN THE EXECUTIVE COMMITEE AND FINANCE COMMITTEE BOARD OF DIRECTOR MEETING MINUTES. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS OF THE ORGANIZATION ARE AVAILABLE ON THE ORGANIZATION'S WEBSITE, AND UPON REQUEST. THESE DOCUMENTS HAVE BEEN PROVIDED TO A THIRD PARTY WEBSITE "CHARITY NAVIGATOR: YOUR GUIDE TO INTELLIGENT GIVING." FORM 990, PART IX, LINE 11G CONSULTING FEES: PROGRAM SERVICE EXPENSES 1,706,867. MANAGEMENT AND GENERAL EXPENSES 15,000. FUNDRAISING EXPENSES 7,087. TOTAL EXPENSES 1,728,954. PART XII, LINE 2C THE AUDIT OVERSIGHT COMMITTEE HAS NOT CHANGED ITS PROCESS SINCE THE PRIOR YEAR.